Valproic Acid: Special Considerations and Targeted Monitoring

Collins‐Yoder, Angela; Lowell, Jordan

doi:10.1097/jnn.0000000000000259

Cited by 8 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the designed sensor behaved satisfactorily within the concentration of 5–75 μg ml −1 , its response range failed to completely cover the VPA therapeutic window (50–100 μg ml −1 ) ( Collins-Yoder and Lowell, 2017 ; Verrotti et al, 2020 ). Generally, when VPA is used to treat BD, its blood concentration needs to be above 50 μg ml −1 .…”

Section: Resultsmentioning

confidence: 95%

“…In this work, prior to measurements, ppy@AuNPs-MIP-modified SPEs were incubated in a series of VPA solutions (concentrations ranged from 5 μg ml −1 -75 μg ml −1 ) for 8 min under mild stirring. Although the designed sensor behaved satisfactorily within the concentration of 5-75 μg ml −1 , its response range failed to completely cover the VPA therapeutic window (50-100 μg ml −1 ) (Collins-Yoder and Lowell, 2017;Verrotti et al, 2020). Generally, when VPA is used to treat BD, its blood concentration needs to be above 50 μg ml −1 .…”

Section: Determination Of Vpamentioning

confidence: 96%

See 1 more Smart Citation

A One-Step Electropolymerized Biomimetic Polypyrrole Membrane-Based Electrochemical Sensor for Selective Detection of Valproate

Yuan

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Bipolar disorder is a chronic mental disease with a heavy social and economic burden that causes extreme mood swings in patients. Valproate is a first-line drug for bipolar disorder patients to stabilize their daily mood. However, an excessive amount of valproate in the blood could induce severe adverse effects, which necessitates the monitoring of blood valproate levels for patients. Here, we developed an innovative electrochemical sensor for selective and simple detection of valproate based on a molecularly imprinted polymer membrane via one-step electropolymerization. Gold nanoparticles were electrochemically modified to the screen-printed electrode under the selective membrane to enhance its conductivity and stability. The successfully fabricated biosensor was characterized by scanning electron microscopy, cyclic voltammetry, and differential pulse voltammetry methods. The binding of the target molecules to the valproate-customized biomimetic polypyrrole membrane blocks cavities in the membrane and alters its electric properties, which can be detected as a decrease in the peak current by differential pulse voltammetry method. The peak current change presents a great log-linear response to the valproate concentration around the therapeutic window. The limit of detection of this method was 17.48 μM (LOD, S/N = 3) and the sensitivity was 31.86 μM μA−1. Furthermore, the biosensors exhibited both satisfying specificity with the interference of other psychological pharmaceutical drugs and uniformity among sensors, indicating their potential and reliability in translational application. This simple and reliable method of sensing valproate molecules primarily provides an exceptional solution to valproate point-of-care testing in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Determination Of Vpamentioning

confidence: 96%

A One-Step Electropolymerized Biomimetic Polypyrrole Membrane-Based Electrochemical Sensor for Selective Detection of Valproate

Yuan

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…It is possible that the beneficial effect of VPA as a mood stabilizer may also be related to drug-induced M-current increases. Nonetheless, VPA has various mechanism of action that are not related to M current (Tomson et al, 2016;Collins-Yoder and Lowell, 2017). Therefore, a direct link between VPAinduced facilitation of M current and its effect as a mood stabilizer remains to be proven.…”

Section: Bipolar Disordermentioning

confidence: 99%

Pharmacological Manipulation of Kv7 Channels as a New Therapeutic Tool for Multiple Brain Disorders

Vigil¹,

Carver²,

Shapiro³

2020

Front. Physiol.

View full text Add to dashboard Cite

K v 7 ("M-type," KCNQ) K + currents, play dominant roles in controlling neuronal excitability. They act as a "brake" against hyperexcitable states in the central and peripheral nervous systems. Pharmacological augmentation of M current has been developed for controlling epileptic seizures, although current pharmacological tools are uneven in practical usefulness. Lately, however, M-current "opener" compounds have been suggested to be efficacious in preventing brain damage after multiple types of insults/diseases, such as stroke, traumatic brain injury, drug addiction and mood disorders. In this review, we will discuss what is known to date on these efforts and identify gaps in our knowledge regarding the link between M current and therapeutic potential for these disorders. We will outline the preclinical experiments that are yet to be performed to demonstrate the likelihood of success of this approach in human trials. Finally, we also address multiple pharmacological tools available to manipulate different K v 7 subunits and the relevant evidence for translational application in the clinical use for disorders of the central nervous system and multiple types of brain insults. We feel there to be great potential for manipulation of K v 7 channels as a novel therapeutic mode of intervention in the clinic, and that the paucity of existing therapies obligates us to perform further research, so that patients can soon benefit from such therapeutic approaches.

show abstract

“…Therapeutic drug monitoring of VPA is a key aspect of the drug treatment of epilepsy because the therapeutic window of VPA is relatively narrow and there are many factors that affect the serum drug concentration. The current reference treatment range of VPA for epilepsy recommended by existing guidelines is 50 to 100 mg/L [ 2 , 3 ]. When the serum drug concentration is lower than required for treatment, the symptoms of epilepsy are not well controlled, and when the concentration is exceeded, the risk of adverse drug reactions increases, including those of the digestive system, nervous system, and hematological system [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis

Lan

et al. 2021

Med Sci Monit

View full text Add to dashboard Cite

Background We aimed to explore the risk factors that affect the serum concentration of sodium valproate (VPA-Na) in patients with epilepsy and to provide references for the rationale of the use of VPA-Na. Material/Methods The enzyme-multiplied immunoassay technique was used to determine the serum VPA-NA concentrations of 109 patients, and the results were retrospectively analyzed and summarized. A multivariate logistic regression model was used to analyze substandard serum VPA-Na concentrations. Results Fifty-six patients (51.38%) treated with VPA-Na tablets were within the effective treatment range of 50–100 μg/mL, while 53 patients (48.62%) were out of the treatment range. The results indicated that the standard-reaching rate of serum drug concentration in the juvenile group was higher than that in the adult and elderly groups; the standard-reaching rates of serum drug concentrations in the low-dose group and the intermediate-dose group were lower than that in the high-dose group; and the standard-reaching rate of serum drug concentration in the group receiving carbapenems in combination was lower than that in the non-combination group; all differences were statistically significant. The combination with carbapenems and enzyme inducers was an independent risk factor for VPA-Na serum concentration below the target level in hospitalized patients. Conclusions To improve clinical efficacy and reduce the occurrence of adverse reactions, there is a need for therapeutic drug monitoring of VPA-Na. Moreover, individual administration should be implemented when VPA-Na tablets are used in the treatment of epilepsy because of the significant fluctuation in VPA-Na blood concentration.

show abstract

Valproic Acid: Special Considerations and Targeted Monitoring

Cited by 8 publications

References 4 publications

A One-Step Electropolymerized Biomimetic Polypyrrole Membrane-Based Electrochemical Sensor for Selective Detection of Valproate

A One-Step Electropolymerized Biomimetic Polypyrrole Membrane-Based Electrochemical Sensor for Selective Detection of Valproate

Pharmacological Manipulation of Kv7 Channels as a New Therapeutic Tool for Multiple Brain Disorders

Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis

Contact Info

Product

Resources

About